Women’s Health Policy

A new KFF analysis reviews exceptions to abortion bans and describes how the stated aim to provide life-saving and health-preserving abortion care may not be achieved in practice. Abortion is currently banned in 14 states and many other states have attempted to ban or severely restrict abortion access. Exceptions to…

This policy watch explains the April 21, 2023 United States Supreme Court’s ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA’s approval of mifepristone, the medication abortion pill.

This policy watch explains the two conflicting rulings on the provision of mifepristone issued by two separate District Courts on April 7, 2023, Alliance for Hippocratic Medicine v. FDA and State of Washington v. United States Food and Drug Administration.

According to a new KFF survey with a nonprobability sample of clients from four online sources of contraception, one in four clients said they got emergency contraception to have on hand because of the Supreme Court’s decision to overturn Roe v. Wade. Additionally, more than a fifth (22%) said they…

Based on the findings of a nonprobability sample of 6,000 survey respondents from four telecontraception companies, this brief presents a snapshot of telecontraception users and their reasons for using these platforms.

The provision of the Affordable Care Act (ACA) that requires most private health plans to cover many preventive services without any cost-sharing for their enrollees is being challenged in federal court. The U.S. District Court in the Northern District of Texas in September concluded that aspects of the requirement were…

In anticipation of a ruling in a case with enormous implications for access to medication abortion in the United States, a new KFF brief explains the impact of this case, and others filed in federal courts, involving the FDA’s regulation of medication abortion. The case that has gotten the most…

This issue brief details the Alliance of Hippocratic Medicine challenge to the FDA’s approval of the abortion pill, mifepristone. It provides context for the challenge, as well as what some of the possible rulings in the case could mean for access to medication abortion.

Access to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion. Mifepristone, approved by the FDA in 2000,…